10-Q: GoHealth Navigates Losses with Strategic Debt Overhaul

GoHealth, Inc. reported increased net losses for Q2 2025 and H1 2025, alongside a significant intangible asset impairment, but secured new financing and debt amendments to alleviate going concern doubts.

Summary

• Net revenues decreased by 11.2% to $94.0 million for the three months ended June 30, 2025, compared to $105.9 million in the prior year period, primarily due to a deliberate pullback in Medicare Advantage activity.
• Net revenues increased by 8.1% to $315.0 million for the six months ended June 30, 2025, compared to $291.5 million in the prior year period, driven by a shift from non-agency to agency revenue.
• Net loss attributable to GoHealth, Inc. widened to $54.3 million for Q2 2025 (from $26.0 million in Q2 2024) and to $58.7 million for H1 2025 (from $35.2 million in H1 2024).
• Basic and diluted net loss per share increased to $5.10 for Q2 2025 and $5.72 for H1 2025.
• Adjusted EBITDA improved to a loss of $11.3 million for Q2 2025 (from a loss of $12.3 million in Q2 2024) and increased to $30.8 million for H1 2025 (from $14.6 million in H1 2024).
• The company recorded a $53.0 million intangible asset impairment charge on indefinite-lived trade names for the three and six months ended June 30, 2025, due to a revised long-term forecast.
• Submissions decreased by 7.5% to 140,991 for Q2 2025 but increased by 20.5% to 444,103 for H1 2025.
• Sales per Submission decreased by 4.8% to $657 for Q2 2025 and by 10.7% to $703 for H1 2025, primarily due to the shift in focus to GoHealth Protect, which yields lower per-submission revenue.
• Direct Operating Cost per Submission decreased by 4.4% to $613 for Q2 2025 and by 13.9% to $551 for H1 2025, attributed to improved agent productivity and technology investments.
• The company secured a new $115.0 million Superpriority Facility on August 6, 2025, consisting of $80.0 million in new-money term loans and $35.0 million in roll-up term loans, alleviating prior going concern doubts.
• As part of the new financing, GoHealth issued 4,766,219 shares of Class A common stock to lenders, representing 16.66% of total outstanding Class A and Class B common stock post-closing.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative. While the company successfully addressed immediate going concern issues through significant debt restructuring and new capital, this came at the cost of substantial shareholder dilution and increased long-term debt. The large intangible asset impairment charge and widening net losses indicate underlying operational challenges. The strategic shift and new product lines offer potential, but their positive impact is not yet fully realized, and ongoing legal proceedings pose a significant risk.

Positives

• Adjusted EBITDA improved for the three months ended June 30, 2025, and significantly increased for the six months ended June 30, 2025, reflecting improved operating efficiencies.
• Direct Operating Cost per Submission decreased by 4.4% for Q2 2025 and 13.9% for H1 2025, indicating better cost management and agent productivity.
• The company successfully secured a new $115.0 million Superpriority Facility and amended existing debt agreements, alleviating substantial doubt about its ability to continue as a going concern.
• Principal payments on the Existing Term Loan Facility are waived until December 31, 2026, providing near-term cash flow relief.
• A portion of interest on outstanding Existing Term Loans and Class A Revolving Loans can now be paid in-kind, further easing cash burden.
• The Centers for Medicare and Medicaid Services (CMS) announced a 10.72% increase in broker commissions for the 2026 plan year, which could positively impact future agency revenue.
• Launch of 'GoHealth Protect' and continued investment in AI and automation (e.g., PlanFit CheckUp, Customer 360) demonstrate strategic evolution and focus on consumer engagement and operational efficiency.

Negatives

• Net loss attributable to GoHealth, Inc. significantly widened to $54.3 million for Q2 2025 and $58.7 million for H1 2025.
• A substantial $53.0 million intangible asset impairment charge was recorded for indefinite-lived trade names, reflecting a revised long-term forecast and tightening health plan economics.
• Net revenues decreased by 11.2% for Q2 2025, primarily due to a deliberate scaling back of Medicare Advantage activity.
• Sales per Submission decreased by 4.8% for Q2 2025 and 10.7% for H1 2025, partly due to the lower per-submission revenue from the new GoHealth Protect product.
• The company's Class A common stock was diluted by 16.66% post-closing due to the issuance of 4,766,219 shares to lenders as a condition for new financing.
• Long-term debt, net of current portion, increased to $560.0 million as of June 30, 2025, from $447.9 million as of December 31, 2024.
• The company is involved in a legal proceeding with the Department of Justice (DOJ) related to alleged False Claims Act and Anti-Kickback Statute violations, which could result in significant damages and penalties.

Risks

• The company's liquidity condition, while currently alleviated, may deteriorate in the future, or it may be unable to comply with financial covenants under its debt agreements, including the new minimum liquidity covenant in the Superpriority Credit Agreement.
• Sales of a substantial number of newly issued Class A common stock shares by lenders could cause the stock price to fall and further dilute existing shareholders.
• Ongoing legal proceedings, particularly the DOJ intervention in the qui tam action, could lead to significant damages, fines, penalties, revocation of licenses, or changes in business practices, materially affecting financial condition and operations.
• Weakening industry or economic trends, disruptions to the business, or changes in discount rate assumptions could adversely impact the valuation of intangible assets, potentially requiring additional impairment charges.
• Changes and developments in laws and regulations governing health insurance markets, such as CMS rules, could materially affect the business, operating results, and financial condition.
• The company's operating results may be adversely impacted by factors affecting the estimate of Lifetime Value (LTV) of commissions, which is subject to variability based on policy persistency and other factors.

Future Outlook

Management believes current liquidity, including cash from operations, cash equivalents, and proceeds from the new Superpriority Facility, will be sufficient to meet projected operating requirements and debt obligations for the next twelve months, alleviating prior going concern doubts. The company expects GoHealth Protect to be a meaningful contributor to full-year 2025 results and beyond, following its ramp-up in Q2 and expected continued growth in Q3 2025. The company is preparing for and analyzing the implications of the CMS final rate notice for the 2026 plan year, which includes a 5.06% average increase in Medicare Advantage revenue and a 10.72% increase in broker commissions.

Management Comments

• We have evolved from a traditional Medicare enrollment company to a Medicare engagement company, focusing on forging high-quality relationships with our consumers.
• Our Encompass operating model puts the consumer at the center of all our activities, including how we market, support enrollment activities, provide administrative services, utilize our proprietary technology and ultimately deliver a high-quality solution to those we serve.
• The introduction of guaranteed acceptance life insurance is designed to provide a simple, affordable solution to help families cover funeral and burial expenses, aligning with our commitment to offering peace of mind to our consumers.
• We are confident that this product also enables us to better support our existing customer base, many of whom are over 65 or approaching Medicare eligibility.
• As GoHealth Protect was in its early testing phases during the first quarter of 2025, there was minimal contribution to net revenues. However, we ramped up GoHealth Protect in the second quarter and expect it to continue to grow in the third quarter of 2025, positioning GoHealth Protect to be a meaningful contributor to the full year 2025 results and beyond.
• Driven by artificial intelligence (AI) and automation, we continue to enhance our technology platform to improve operational efficiency, scalability and consumer engagement.
• As the landscape becomes more complex, we believe GoHealth’s role as a reliable guide becomes increasingly critical.

Industry Context

The health insurance marketplace, particularly Medicare, is undergoing significant changes driven by regulatory updates (e.g., CMS Final Rule for 2025 and 2026 plan years) and evolving health plan economics. The industry is seeing a shift towards more dynamic consumer shopping behaviors and tightening margins for health plans, leading to adjustments in marketable and commissionable plans. GoHealth's strategic pivot towards a 'Medicare engagement company' and the launch of 'GoHealth Protect' (guaranteed acceptance life insurance) reflect an adaptation to these market dynamics, aiming to diversify revenue streams and deepen customer relationships beyond initial enrollment. The increased broker commissions announced by CMS for 2026 could be a positive industry trend for companies like GoHealth that rely on commission-based revenue.

Comparison to Industry Standards

• The company's shift from non-agency to agency revenue, partially offset by the expansion of non-agency contracts through GoHealth Protect, indicates an adaptation to changing carrier and product mix within the non-agency channel and consumer needs. This strategic flexibility is crucial in a dynamic market.
• The decrease in Sales per Submission, primarily due to the lower revenue per submission from the new GoHealth Protect product compared to Medicare products, suggests a trade-off between revenue quality and diversification. Competitors focused solely on high-value Medicare Advantage enrollments might show higher per-submission revenue, but potentially less diversified portfolios.
• Improvements in Direct Operating Cost per Submission, driven by agent productivity and technology investments, align with industry efforts to optimize efficiency. Companies like SelectQuote, Inc. and eHealth, Inc. (mentioned in the DOJ lawsuit context) also focus on technology and agent efficiency to manage costs in a competitive landscape.
• The significant intangible asset impairment charge reflects a re-evaluation of long-term forecasts, potentially indicating a more conservative outlook on Medicare Advantage growth compared to prior expectations, a trend that could be observed across the broader Medicare brokerage industry due to tightening health plan economics.

Corporate Governance

Legal Proceedings

• A derivative action filed on May 19, 2021, alleging breaches of fiduciary duty and other claims, based on a now-resolved Securities Class Action. The action was stayed on June 6, 2022, and the company is contesting it but may pursue settlement.
• The Department of Justice (DOJ) intervened in a qui tam proceeding on January 15, 2025, and filed a complaint on May 1, 2025, against GoHealth and other insurers/brokers. Allegations include violations of the False Claims Act and Anti-Kickback Statute related to arrangements with health plan partners and sales/marketing practices. The DOJ seeks treble damages, civil penalties, and costs. The company intends to vigorously defend against these allegations.

Related Party Transactions

• Lease agreements with 220 W Huron Street Holdings LLC, 215 W Superior LLC, and Wilson Tech 5, LLC, entities controlled by significant stockholders of the company.
• Aggregate lease payments under these agreements were $1.0 million for the three months ended June 30, 2025, and $2.2 million for the six months ended June 30, 2025.

Stakeholder Impact

• Shareholders face significant dilution from the recent issuance of Class A common stock to lenders and potential further dilution from future equity raises.
• Shareholders are exposed to financial risks from ongoing legal proceedings, which could result in substantial damages or operational restrictions.
• Employees may experience changes in compensation structures and incentive plans as the Transformation Committee reviews these arrangements.
• Health plan partners may see changes in GoHealth's focus and offerings, with a deliberate pullback in Medicare Advantage activity and a shift towards agency revenue and new products like GoHealth Protect.
• Creditors and lenders benefit from the new Superpriority Facility, which provides payment priority and amended covenants, improving the company's ability to meet debt obligations, but also indicates the company's prior financial distress.

Next Steps

• Continue to ramp up 'GoHealth Protect' in the third quarter of 2025, expecting it to be a meaningful contributor to full-year 2025 results.
• Monitor and analyze the implications of the CMS final rate notice on commissions for the 2026 plan year with health plan partners.
• The Transformation Committee will review, formulate, and negotiate various strategic alternatives, including refinancings, securitizations, mergers, acquisitions, or restructurings.
• The Transformation Committee will work with the Compensation Committee to review and recommend future employee incentive plans and compensation arrangements.
• Vigorously defend against the Department of Justice's allegations in the qui tam proceeding, while potentially pursuing settlement negotiations.

Key Dates

Recommendation

While GoHealth has taken critical steps to address its immediate liquidity and going concern issues through a significant debt restructuring and new capital infusion, the financial results for the quarter show continued net losses and a substantial intangible asset impairment. The dilution from the new equity issuance to lenders is notable. The strategic shift towards 'GoHealth Protect' and improved operating efficiencies are positive long-term indicators, but the ongoing DOJ legal proceedings present a material, unquantifiable risk. Given the mixed financial performance, the dilution, and the legal uncertainties, a 'hold' recommendation is appropriate as investors await clearer signs of sustained profitability and resolution of legal matters.

Keywords

Medicare, Health Insurance, Digital Health, SEC Filing, 10-Q, Financial Results, Debt Restructuring, Impairment, Legal Proceedings, Healthcare Technology, Insurance Brokerage, GoHealth Protect, AI, Automation